Cd44 Targeted Delivery of Hyaluronic Acid-Coated Polymeric Nanoparticles Against Colorectal Cancer

Abstract

Aim: To develop hyaluronic acid (HA)-coated poly-lactic-co-glycolic acid (PLGA)-polysarcosine (PSAR) coupled sorafenib tosylate (SF) polymeric nanoparticles for targeted colon cancer therapy. Materials & methods: PLGA–PSAR shells were encapsulated with SF via nanoprecipitation. Interactions were examined with transmission electron microscopy, revealing formulation component interactions. Results: The optimized HA-coated polymeric nanoparticles (238.8 nm, -6.1 mV, 68.361% entrapment) displayed enhanced controlled release of SF. These formulations showed superior cytotoxicity against HCT116 cell lines compared with free drug (p < 0.05). In vivo tests on male albino Wistar rats demonstrated improved pharmacokinetics, targeting and biocompatibility. HA-coated PLGA–PSAR-coupled SF polymeric nanoparticles hold potential for effective colorectal therapy. Conclusion: Colon cancer may be precisely targeted by HA-coated PLGA–PSA-coupled SF polymeric nanoparticles.

Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers

“…In Liu et al’s work [ 92 ], EVs were first conjugated to galactose to protect the drug from degradation in the stomach; then, a chitosan/alginate hydrogel was used to coat the EVs to ensure a favorable delivery to the colonic tract. Similarly, hyaluronic acid (HA) and its conjugates have been used to formulate nanocarriers for IBD treatment [ 93 , 94 , 95 ] and for colon cancer drug delivery [ 96 , 97 ]. HA is an unbranched glycosaminoglycan component of the extracellular matrix.…”